Sana Biotechnology, Inc. (SANA) financial statements (2022 and earlier)

Company profile

Business Address 188 EAST BLAINE STREET, SUIT 400
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments551
Cash and cash equivalents253
Short-term investments298
Other undisclosed current assets7
Total current assets:558
Noncurrent Assets
Operating lease, right-of-use asset96
Property, plant and equipment65
Long-term investments and receivables196
Long-term investments196
Intangible assets, net (including goodwill)200
Goodwill141
Intangible assets, net (excluding goodwill)59
Restricted cash and investments9
Other noncurrent assets5
Total noncurrent assets:571
TOTAL ASSETS:1,129
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28
Accounts payable2
Accrued liabilities4
Employee-related liabilities21
Business combination, contingent consideration, liability51
Other undisclosed current liabilities20
Total current liabilities:99
Noncurrent Liabilities
Long-term debt and lease obligation102
Operating lease, liability102
Liabilities, other than long-term debt102
Business combination, contingent consideration, liability102
Other undisclosed noncurrent liabilities98
Total noncurrent liabilities:302
Total liabilities:401
Stockholders' equity
Stockholders' equity attributable to parent729
Common stock0
Additional paid in capital1,515
Accumulated other comprehensive loss(1)
Accumulated deficit(785)
Total stockholders' equity:729
TOTAL LIABILITIES AND EQUITY:1,129

Income statement (P&L) ($ in millions)

12/31/2021
Operating expenses(357)
Operating loss:(357)
Nonoperating income
(Other Nonoperating income)
0
Loss from continuing operations before equity method investments, income taxes:(357)
Other undisclosed income from continuing operations before income taxes1
Net loss available to common stockholders, diluted:(356)

Comprehensive Income ($ in millions)

12/31/2021
Net loss:(356)
Comprehensive loss:(356)
Other undisclosed comprehensive loss, net of tax, attributable to parent(1)
Comprehensive loss, net of tax, attributable to parent:(357)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: